Your Source for Venture Capital and Private Equity Financings

VC-funded Company:

Arvinas
5 Science Park
395 Winchester Ave.
New Haven, CT 06511
Phone: 203-535-1456

Arvinas Inc. is creating a new class of drugs based on protein degradation, which has the potential to open up areas of drug development that were previously closed because of the technical limitations of target inhibition. The company's technology is built on the research of Craig Crews, PhD of Yale University, and has primary application in oncology indications as well as potential in inflammatory, autoimmune and rare diseases.

Key Contact
Name
Manuel Litchman
Title
CEO
Funding Events

Date
Amount
Type
Investors
Valuation
09/26/13 $15,000,000 Series A 5AM Ventures
Canaan Partners
Connecticut Innovations
Elm Street Ventures
undisclosed
10/21/15 $41,600,000 Series B 5AM Ventures
Canaan Partners
New Leaf Venture Partners
OrbiMed Advisors
RA Capital
undisclosed
04/04/18 $55,000,000 Series C 5AM Ventures
Canaan Partners
Deerfield Management Company, L.P.
Hillhouse Capital Group
New Leaf Venture Partners
Nextech Invest
OrbiMed Advisors
RA Capital
Sirona Capital
undisclosed